Prednison acis 20 mg

DRUG4 trials

Sponsors

Janssen - Cilag International, Macrogenics Inc., AbbVie Deutschland GmbH & Co. KG

Conditions

Chronic Graft Versus Host Disease (cGVHD)Geographic AtrophyMetastatic Castration-resistant Prostate Cancer

Phase 1

Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD)

CompletedCTIS2023-507330-24-00

AbbVie Deutschland GmbH & Co. KGChronic Graft Versus Host Disease (cGVHD)

Start: 2019-02-07End: 2025-01-20Target: 14Updated: 2024-12-17

Phase 2

A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)

CompletedCTIS2022-501078-20-00

Macrogenics Inc.Metastatic Castration-resistant Prostate Cancer

Start: 2023-05-15End: 2025-01-23Target: 61Updated: 2025-02-04

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Active, not recruitingCTIS2022-500746-16-00

Janssen - Cilag InternationalGeographic Atrophy

Start: 2023-08-11Target: 118Updated: 2025-12-15

Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

RecruitingCTIS2022-500747-21-00

Janssen - Cilag InternationalGeographic Atrophy

Start: 2025-02-27Target: 120Updated: 2025-08-25